NYSE:RCUS Arcus Biosciences Q4 2024 Earnings Results & Report $22.84 +0.33 (+1.45%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more. Arcus Biosciences beat analyst expectations on both earnings and revenue in its Q4 2024 results, released February 25, 2025. The company reported EPS of -$1.03 versus the -$1.17 consensus estimate, while revenue of $36.00 million topped the $29.38 million estimate by $6.63 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateFebruary 25, 2025TimeAfter Market ClosesConference Call4:05 PM ET Arcus Biosciences EPS ResultsActual EPS-$1.03Consensus EPS -$1.17Beat/MissBeat by +$0.14One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersArcus Biosciences Revenue ResultsActual Revenue$36.00 millionExpected Revenue$29.38 millionBeat/MissBeat by +$6.63 millionYoY Revenue GrowthN/AUpcoming EarningsArcus Biosciences' Q3 2026 earnings is estimated for Tuesday, October 27, 2026, based on past reporting schedulesConference Call ResourcesSlide DeckPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Arcus Biosciences Q4 2024 Earnings FAQ Did Arcus Biosciences beat earnings estimates for Q4 2024? Arcus Biosciences (NYSE:RCUS) reported earnings of -$1.03 per share for Q4 2024, beating the consensus estimate of -$1.17. The report was announced on Tuesday, February 25, 2025. What was Arcus Biosciences' revenue for Q4 2024? Arcus Biosciences reported revenue of $36.00 million for Q4 2024, against a consensus estimate of $29.38 million. When is Arcus Biosciences' next earnings date? Arcus Biosciences' next earnings date is estimated for Tuesday, October 27, 2026. MarketBeat tracks confirmed and estimated earnings dates for Arcus Biosciences on the company's earnings history page. Arcus Biosciences Earnings HeadlinesJPMorgan Initiates Coverage on Arcus Biosciences With Overweight Rating, $41 Price Target3 hours ago | marketscreener.comMArcus Biosciences, Inc. (NYSE:RCUS) Stock Has Average Price Target of $38.30October 11 at 2:15 AM | americanbankingnews.comHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling shares or trading options, but simply by holding the fund and letting it pay out cash every Thursday. That works out to a 34% annualized distribution rate, even though the underlying AI stocks pay no dividends themselves. Tim Plaehn, Chief Income Strategist at Investors Alley, breaks down exactly how the fund generates these weekly payouts.October 14 at 1:00 AM | Investors Alley (Ad)Arcus Biosciences Announces New Employment Inducement GrantsOctober 9, 2026 | businesswire.comArcus Biosciences Completes Early Cancer Trial for AB801, Setting Up Next Pipeline MovesOctober 9, 2026 | tipranks.comIs Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?October 7, 2026 | finance.yahoo.comSee More Arcus Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcus Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcus Biosciences and other key companies, straight to your email. Email Address About Arcus BiosciencesArcus Biosciences (NYSE:RCUS) is a biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses a proprietary research platform to develop small-molecule and antibody-based therapies designed to target biological mechanisms involved in tumor growth and immune-system regulation. Arcus’ oncology pipeline has included investigational therapies such as zimberelimab, an anti-PD-1 antibody; domvanalimab, an anti-TIGIT antibody; quemliclustat, a CD73 inhibitor; and etrumadenant, an adenosine receptor antagonist. These candidates are being evaluated in combination regimens and across multiple cancer types, including lung and gastrointestinal cancers. The company does not have a broad portfolio of marketed products and remains primarily focused on clinical-stage development. Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical development activities through collaborations and studies involving institutions and patients in the United States and other international markets. The company has maintained a strategic partnership with Gilead Sciences to advance and commercialize certain oncology programs. Arcus was co-founded and is led by Terry Rosen, Ph.D., who serves as chief executive officer.View Arcus Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
